Welcome to our dedicated page for Bausch + Lomb news (Ticker: BLCO), a resource for investors and traders seeking the latest updates and insights on Bausch + Lomb stock.
Bausch + Lomb Corporation reports developments across its global eye health business, including vision care, surgical devices and ophthalmic pharmaceuticals. Recurring updates cover contact lenses and lens care products, eye vitamins and redness-relief drops, dry eye and prescription ophthalmology brands, intraocular lenses, vitrectomy cutters and the Stellaris Elite Vision Enhancement System.
Company news also includes financial results and guidance, scientific presentations, R&D pipeline discussions, FDA 510(k) clearances, European product launches and sustainability programs such as ONE by ONE Recycling. Product-specific coverage frequently references Biotrue, LUMIFY, XIIDRA, MIEBO, PreserVision, INFUSE, ULTRA ONE DAY, enVista and Bi-Blade technologies.
Bausch Health (NYSE: BHC) announced that its CEO, Thomas J. Appio, has been appointed to the board of directors of Bausch + Lomb (NYSE: BLCO), effective August 5, 2026. Bausch + Lomb is described as a key asset of Bausch Health.
Additional directors Robert J. Chersi, Laurence E. Paul, M.D., and Barbara J. Trebbi also joined the Bausch + Lomb board. They replace Steven Collis, Karen Ling, Thomas Ross and Andrew von Eschenbach, MD, who resigned without any stated disagreements with Bausch + Lomb. Bausch Health remains Bausch + Lomb’s largest shareholder, indirectly holding about 87% of its outstanding common shares, and requested these board changes in line with its ownership position.
Bausch + Lomb (NYSE/TSX: BLCO) announced Board changes effective Aug. 5, 2026, appointing four new directors at the request of majority owner Bausch Health, which holds approximately 87% of outstanding common shares. Four current directors resigned to facilitate the refresh, and the company said none resigned due to disagreement.
Bausch + Lomb reported second-quarter 2026 revenue of $1.394 billion, up 9% reported and 8% in constant currency versus 2025, with broad-based segment growth and margin expansion. Net operating cash flow rose from $32 million in Q1 to $153 million in Q2, while adjusted cash flow from operations increased from $45 million to $161 million. The company reaffirmed its previously raised 2026 guidance, targeting full-year revenue of $5.440–$5.540 billion and Adjusted EBITDA excluding Acquired IPR&D (non-GAAP) of $1.025–$1.075 billion.
Bausch + Lomb (NYSE/TSX: BLCO) reported second-quarter 2026 revenue of $1.394 billion, up 9% reported and 8% in constant currency versus 2025, with growth across Vision Care, Surgical and Pharmaceuticals. Surgical revenue rose 19%, Pharmaceuticals 15% and Vision Care 4%.
Operating results shifted to $83 million of operating income from an $11 million loss, while GAAP net loss improved to $14 million from $62 million. Adjusted net income rose to $55 million and adjusted EBITDA excluding acquired IPR&D increased to $246 million. Cash flow from operations grew to $153 million from $35 million.
According to Bausch + Lomb, full-year 2026 guidance was raised to revenue of $5.44–$5.54 billion and adjusted EBITDA excluding acquired IPR&D of $1.025–$1.075 billion. The company also reported topline pivotal data for the enVista Beyond investigational IOL, showing improved intermediate vision and depth of focus versus a monofocal lens, a favorable safety profile and narrowly missed predefined performance targets.
Bausch + Lomb (NYSE/TSX: BLCO) announced the U.S. launch of the EyeGility Inserter, a preloaded intraocular lens (IOL) delivery system designed for the enVista Aspire and Envy IOL families. EyeGility offers one-handed operation, balanced push force for smooth IOL delivery and a silicone soft-tipped plunger, allowing injection through a 2.4 mm incision and up to 20 minutes of standby time from preparation to lens delivery.
According to the company, EyeGility is now available in the U.S. with enVista Aspire preloaded IOLs, with enVista Envy lenses preloaded into EyeGility expected in the coming months. The release details indications, precautions, warnings and potential adverse events for the EyeGility inserter, enVista Aspire hydrophobic acrylic IOL and enVista Envy non-toric and toric hydrophobic acrylic IOLs, emphasizing physician judgment, patient selection and adherence to Directions for Use and federal law restrictions.
Bausch + Lomb (NYSE/TSX: BLCO) reported topline Phase 2 results for glaucoma candidate BL1107. The 159-patient study did not meet its primary visual field endpoint or key visual function secondary endpoints after 28 days of topical dosing.
The company will discontinue BL1107 as a glaucoma eye drop and concentrate on developing a sustained-release implant for geographic atrophy, with clinical trials expected in 2028. According to Bausch + Lomb, BL1107 showed intraocular pressure reduction and a safety profile consistent with prior experience. The firm highlights a diversified pipeline of more than 60 assets with multiple anticipated milestones across Consumer, Pharmaceuticals, Surgical and Vision Care segments.
Bausch + Lomb (NYSE/TSX: BLCO) launched Orphia, an AI-powered digital health platform designed to reduce operational burdens so eye care providers can focus more on patient care. The brand-agnostic platform’s first application supports pre-surgery cataract education and integrates with existing practice systems.
Orphia is developed with voice AI partner Hippocratic AI and will operate within Bausch + Lomb’s new Digital Health Services platform, led by Manisha Narasimhan, PhD, with plans to expand across the full ophthalmology patient journey over time.
Bausch + Lomb (NYSE:BLCO) will release its Q2 2026 financial results on Wednesday, July 29, 2026. Management will host a conference call and live webcast at 8 a.m. ET to discuss results and provide a business update.
Materials will be available in the Investor Relations section of the company website before the call.
Bausch + Lomb (NYSE/TSX: BLCO) reported new data from its third annual State of Dry Eye survey of 1,000 treated dry eye sufferers, highlighting emotional and quality-of-life impacts.
Findings link symptom relief with improved self-confidence, emotional wellbeing, productivity and mood, and reveal low awareness of links to hormonal and autoimmune conditions.
Bausch + Lomb (NYSE:BLCO) announced the U.S. launch of Blink Triple Care Preservative Free lubricant eye drops, a multi-dose, preservative-free version of the existing Blink Triple Care formula.
The lipid- and water-based drops use a natural oil and hyaluronate to create a dual-action moisture seal, offering 3‑in‑1 extended relief and up to 10 hours of dry eye symptom relief. The product is expected to be available at most major U.S. retailers and online, including Amazon, CVS, Target and Walgreens, by the end of June 2026.
Bausch + Lomb (NYSE:BLCO) announced that Chairman and CEO Brent Saunders and Chief Medical Officer and Head of R&D Yehia Hashad will join a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami on June 9, 2026, at 1:20 p.m. ET. A live webcast will be accessible via the company’s investor relations website.